Echo IQ (ASX:EIQ): What Are Investors Watching After the FDA Update?

Sonal Goyal

16 September 2026 12:21 AM AEST

Echo IQ (ASX:EIQ): What Are Investors Watching After the FDA Update?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Echo IQ Limited (ASX:EIQ) develops artificial intelligence-based decision-support technology for structural heart disease assessment. The company’s September 2026 update highlighted a regulatory setback for its EchoSolv HF product, while its cleared EchoSolv AS product continued to support commercialisation efforts. Regulatory progress, product adoption and Cash Management remain key areas of focus following the latest developments.

FDA Update

Echo IQ advised the market in September 2026 that the United States Food and Drug Administration issued a Not Substantially Equivalent determination for the initial 510(k) submission of EchoSolv HF.

Business Operations

Echo IQ develops artificial intelligence decision-support solutions designed to assist clinicians assessing structural heart conditions.

The company’s technology uses measurements captured from routine cardiac imaging procedures to provide clinical assessments at the point of decision-making. EchoSolv AS focuses on aortic stenosis assessment and has received regulatory clearance for use in the United States.

Echo IQ is headquartered in Sydney and has been listed on the ASX since 2010.

Commercial Progress

The company continues to focus on expanding adoption of EchoSolv AS following its regulatory clearance in the United States.

Key areas to monitor include progress in healthcare system adoption, customer engagement and the pace of commercial development as the company builds its presence in the medical technology market.

Risks

Echo IQ remains exposed to regulatory outcomes, as demonstrated by the FDA decision regarding EchoSolv HF.

Commercial adoption of medical technology can take time due to healthcare procurement processes and market acceptance. The company also operates in a competitive artificial intelligence healthcare environment, while future funding requirements may depend on the pace of commercial progress and expenditure.

FAQs

Q: What is the ASX ticker for Echo IQ Limited?

A: Echo IQ Limited trades under the ticker (ASX:EIQ).

Q: What was the key September 2026 update from Echo IQ?

A: The company received a Not Substantially Equivalent determination from the FDA for the initial 510(k) submission of EchoSolv HF.

Q: Which Echo IQ product has received FDA clearance?

A: EchoSolv AS has received FDA clearance for use in the United States.

Q: What factors are important for Echo IQ going forward?

A: Key factors include regulatory progress, commercial adoption of EchoSolv AS, healthcare market expansion and cash management.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.